Shares jumped over 14% on Thursday to their highest level and strongest session since December, when the company reported strong DMD trial results.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On